Literature DB >> 24036918

Clinical features and treatment strategies for older prostate cancer patients with bone metastasis.

Cheng Yang1, Gui-Sheng Qi, Rui-Ming Rong, Jian He.   

Abstract

To identify the clinical features and independent predictors of survival in older patients with bone metastasis from prostate cancer (PCa). We retrospectively analysed 205 older patients with bone metastases from PCa between 1997 and 2012. The Kaplan-Meier method was used with the log-rank test for survival rate calculations and to evaluate each variable. Multivariate analysis was performed with the Cox regression model. The chi-squared test was used to compare survival rates between older and younger (n=197) patients. All patients were followed up. The 1-, 2-, 3- and 5-year survival rates were 95.5%, 77.5%, 68.5% and 33.7%, respectively. Gleason score, radiotherapy of the primary tumour, the number of bone metastases, the alkaline phosphatase alkaline phosphatase (ALP) level, organ metastasis and regional lymph node metastasis were associated with the survival rates. Multivariate Cox regression analysis showed that Gleason score at diagnosis of the primary tumour was a significant predictor of overall survival following the diagnosis of bone metastases. In addition, the overall survival rates of older patients were higher compared with younger patients, but older patients who underwent radiotherapy had higher mortality. These data may serve as a guide for creating clinical prediction models in further studies.

Entities:  

Mesh:

Year:  2013        PMID: 24036918      PMCID: PMC3854036          DOI: 10.1038/aja.2013.111

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  19 in total

1.  Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2.

Authors:  T Jørgensen; Y Kanagasingam; O Kaalhus; K J Tveter; M Bryne; F Skjørten; A Berner; H E Danielsen
Journal:  J Urol       Date:  1997-07       Impact factor: 7.450

2.  Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning.

Authors:  Tracy R Glass; Catherine M Tangen; E David Crawford; Ian Thompson
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

3.  Costs of prostate cancer, metastatic to the bone, in the Netherlands.

Authors:  M T Groot; C G G Boeken Kruger; R C M Pelger; C A Uyl-de Groot
Journal:  Eur Urol       Date:  2003-03       Impact factor: 20.096

4.  TWIST modulates prostate cancer cell-mediated bone cell activity and is upregulated by osteogenic induction.

Authors:  Hiu-Fung Yuen; Wai-Kei Kwok; Ka-Kui Chan; Chee-Wai Chua; Yuen-Piu Chan; Ying-Ying Chu; Yong-Chuan Wong; Xianghong Wang; Kwok-Wah Chan
Journal:  Carcinogenesis       Date:  2008-05-02       Impact factor: 4.944

5.  Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.

Authors:  John C Cheville; Donald Tindall; Christopher Boelter; Robert Jenkins; Christine M Lohse; V Shane Pankratz; Thomas J Sebo; Brian Davis; Michael L Blute
Journal:  Cancer       Date:  2002-09-01       Impact factor: 6.860

6.  Carcinoma of the prostate with soft tissue or non-regional lymphatic metastases at the time of diagnosis: a review of 47 cases.

Authors:  G Saeter; S D Fosså; S Ous; G P Blom; O Kaalhus
Journal:  Br J Urol       Date:  1984-08

7.  Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: a single institution analysis.

Authors:  Alessia Guarneri; Angela Botticella; Andrea Riccardo Filippi; Andrea Ruggieri; Cristina Piva; Fernando Munoz; Riccardo Ragona; Paolo Gontero; Umberto Ricardi
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-04       Impact factor: 4.553

8.  Clinical outcome of Taiwanese men with metastatic prostate cancer compared with other ethnic groups.

Authors:  Chung-Hsin Chen; Tzong-Shin Tzai; Shu-Pin Huang; Hsi-Chin Wu; Huai-Ching Tai; Yen-Hwa Chang; Yeong-Shiau Pu
Journal:  Urology       Date:  2008-04-18       Impact factor: 2.649

9.  Analysis of survival of prostate cancer patients in Japan and the U.S.A.

Authors:  K Imai; T Suzuki; T Shimizu; H Yamanaka; H Kanetake; H Sakai; Y Minami; Y Saito
Journal:  Adv Exp Med Biol       Date:  1992       Impact factor: 2.622

10.  Ten-year survival in patients with metastatic prostate cancer.

Authors:  Catherine M Tangen; James R Faulkner; E David Crawford; Ian M Thompson; Daisaku Hirano; Mario Eisenberger; Maha Hussain
Journal:  Clin Prostate Cancer       Date:  2003-06
View more
  3 in total

1.  Evaluation of vesicular stomatitis virus mutant as an oncolytic agent against prostate cancer.

Authors:  Xin Zhao; Shengsong Huang; Huarong Luo; Xiaodong Wan; Yaping Gui; Junliang Li; Denglong Wu
Journal:  Int J Clin Exp Med       Date:  2014-05-15

2.  Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients.

Authors:  Ting-Ting Lin; Ye-Hui Chen; Yu-Peng Wu; Shao-Zhan Chen; Xiao-Dong Li; Yun-Zhi Lin; Shao-Hao Chen; Qing-Shui Zheng; Yong Wei; Ning Xu; Xue-Yi Xue
Journal:  J Cancer       Date:  2019-09-07       Impact factor: 4.207

3.  Establishing a prediction model for prostate cancer bone metastasis.

Authors:  Song Chen; Lu Wang; Kaiyu Qian; Wei Jiang; Haiqing Deng; Qiang Zhou; Gang Wang; Xuefeng Liu; Chin-Lee Wu; Yu Xiao; Xinghuan Wang
Journal:  Int J Biol Sci       Date:  2019-01-01       Impact factor: 6.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.